questionsmedicales.fr
Cellules
Cellules épithéliales
Hépatocytes
Cellules HepG2
Cellules HepG2 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
2
Carcinome hépatocellulaire
Lignées cellulaires
Culture cellulaire
Microscopie
Symptômes
2
Symptômes
Cellules in vitro
Marqueurs tumoraux
Enzymes hépatiques
Prévention
2
Prévention des maladies
Composés bioactifs
Recherche préventive
Toxines
Traitements
2
Essais cliniques
Toxicité
Développement de médicaments
Mécanismes d'action
Complications
2
Mécanismes pathologiques
Complications hépatiques
Facteurs de risque
2
Facteurs de risque
Toxines
Évaluation des risques
Agents toxiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cellules HepG2 : Questions médicales les plus fréquentes",
"headline": "Cellules HepG2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cellules HepG2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-11",
"dateModified": "2025-02-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cellules HepG2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hépatocytes",
"url": "https://questionsmedicales.fr/mesh/D022781",
"about": {
"@type": "MedicalCondition",
"name": "Hépatocytes",
"code": {
"@type": "MedicalCode",
"code": "D022781",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.436.348"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cellules HepG2",
"alternateName": "Hep G2 Cells",
"code": {
"@type": "MedicalCode",
"code": "D056945",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Wilson de Melo Cruvinel",
"url": "https://questionsmedicales.fr/author/Wilson%20de%20Melo%20Cruvinel",
"affiliation": {
"@type": "Organization",
"name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil. melocruvinel@gmail.com."
}
},
{
"@type": "Person",
"name": "Paulo Luiz Carvalho Francescantonio",
"url": "https://questionsmedicales.fr/author/Paulo%20Luiz%20Carvalho%20Francescantonio",
"affiliation": {
"@type": "Organization",
"name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil."
}
},
{
"@type": "Person",
"name": "Alessandra Dellavance",
"url": "https://questionsmedicales.fr/author/Alessandra%20Dellavance",
"affiliation": {
"@type": "Organization",
"name": "Research and Development Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil."
}
},
{
"@type": "Person",
"name": "Luis Eduardo Coelho Andrade",
"url": "https://questionsmedicales.fr/author/Luis%20Eduardo%20Coelho%20Andrade",
"affiliation": {
"@type": "Organization",
"name": "Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br."
}
},
{
"@type": "Person",
"name": "Antônio Carlos Ximenes",
"url": "https://questionsmedicales.fr/author/Ant%C3%B4nio%20Carlos%20Ximenes",
"affiliation": {
"@type": "Organization",
"name": "Hospital Geral de Goiânia Alberto Rassi, Goiânia, GO, Brazil."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Oxygenolytic sulfoquinovose degradation by an iron-dependent alkanesulfonate dioxygenase.",
"datePublished": "2023-08-31",
"url": "https://questionsmedicales.fr/article/37731605",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.isci.2023.107803"
}
},
{
"@type": "ScholarlyArticle",
"name": "Perfluorooctanoic acid and perfluorooctane sulfonic acid inhibit plant growth through the modulation of phytohormone signalling pathways: Evidence from molecular and genetic analysis in Arabidopsis.",
"datePublished": "2022-08-27",
"url": "https://questionsmedicales.fr/article/36030856",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.scitotenv.2022.158287"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluating perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) removal across granular activated carbon (GAC) filter-adsorbers in drinking water treatment plants.",
"datePublished": "2022-06-03",
"url": "https://questionsmedicales.fr/article/35660589",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.scitotenv.2022.156406"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) on secondary sludge microorganisms: removal, potential toxicity, and their implications on existing wastewater treatment regulations in Canada.",
"datePublished": "2023-10-18",
"url": "https://questionsmedicales.fr/article/37674406",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1039/d3em00202k"
}
},
{
"@type": "ScholarlyArticle",
"name": "High-content analysis shows synergistic effects of low perfluorooctanoic acid (PFOS) and perfluorooctane sulfonic acid (PFOA) mixture concentrations on human breast epithelial cell carcinogenesis.",
"datePublished": "2023-01-12",
"url": "https://questionsmedicales.fr/article/36731186",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.envint.2023.107746"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Cellules",
"item": "https://questionsmedicales.fr/mesh/D002477"
},
{
"@type": "ListItem",
"position": 3,
"name": "Cellules épithéliales",
"item": "https://questionsmedicales.fr/mesh/D004847"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hépatocytes",
"item": "https://questionsmedicales.fr/mesh/D022781"
},
{
"@type": "ListItem",
"position": 5,
"name": "Cellules HepG2",
"item": "https://questionsmedicales.fr/mesh/D056945"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cellules HepG2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cellules HepG2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-30",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cellules HepG2",
"description": "Comment identifier les cellules HepG2 en laboratoire ?\nQuelles techniques sont utilisées pour étudier les HepG2 ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Alkanesulfonic+Acids#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cellules HepG2",
"description": "Les cellules HepG2 présentent-elles des symptômes ?\nQuels marqueurs sont associés aux cellules HepG2 ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Alkanesulfonic+Acids#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cellules HepG2",
"description": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?\nComment les HepG2 contribuent-elles à la recherche préventive ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Alkanesulfonic+Acids#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cellules HepG2",
"description": "Peut-on utiliser HepG2 pour tester des médicaments ?\nComment les HepG2 aident-elles à développer des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Alkanesulfonic+Acids#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cellules HepG2",
"description": "Quelles complications peuvent être étudiées avec HepG2 ?\nLes HepG2 aident-elles à comprendre les complications du foie ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Alkanesulfonic+Acids#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cellules HepG2",
"description": "Quels facteurs de risque sont étudiés avec HepG2 ?\nComment HepG2 aide à identifier des facteurs de risque ?",
"url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Alkanesulfonic+Acids#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les cellules HepG2 en laboratoire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules HepG2 peuvent être identifiées par leur morphologie et leur marqueur spécifique, l'alpha-fœtoprotéine."
}
},
{
"@type": "Question",
"name": "Quelles techniques sont utilisées pour étudier les HepG2 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les techniques incluent la culture cellulaire, la microscopie et les tests de viabilité cellulaire."
}
},
{
"@type": "Question",
"name": "Les cellules HepG2 présentent-elles des symptômes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules HepG2 ne présentent pas de symptômes, car elles sont des cellules in vitro."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés aux cellules HepG2 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cellules HepG2 expriment des marqueurs comme l'alpha-fœtoprotéine et des enzymes hépatiques."
}
},
{
"@type": "Question",
"name": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont utilisées pour étudier les effets préventifs de composés sur les maladies hépatiques."
}
},
{
"@type": "Question",
"name": "Comment les HepG2 contribuent-elles à la recherche préventive ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'analyser les effets de l'alimentation et des toxines sur la santé hépatique."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser HepG2 pour tester des médicaments ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les cellules HepG2 sont souvent utilisées pour évaluer la toxicité et l'efficacité des médicaments."
}
},
{
"@type": "Question",
"name": "Comment les HepG2 aident-elles à développer des traitements ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'étudier les mécanismes d'action des médicaments sur le foie et d'identifier des cibles thérapeutiques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent être étudiées avec HepG2 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications liées aux maladies hépatiques, comme la cirrhose et le cancer du foie, peuvent être modélisées."
}
},
{
"@type": "Question",
"name": "Les HepG2 aident-elles à comprendre les complications du foie ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont essentielles pour étudier les mécanismes des complications hépatiques."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont étudiés avec HepG2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque comme l'alcool, les médicaments et les toxines sont souvent analysés."
}
},
{
"@type": "Question",
"name": "Comment HepG2 aide à identifier des facteurs de risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'évaluer l'impact de divers agents sur la santé des cellules hépatiques."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 05/02/2025
Contenu vérifié selon les dernières recommandations médicales
5 publications dans cette catégorie
Affiliations :
School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil. melocruvinel@gmail.com.
Publications dans "Cellules HepG2" :
5 publications dans cette catégorie
Affiliations :
School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil.
Publications dans "Cellules HepG2" :
4 publications dans cette catégorie
Affiliations :
Research and Development Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil.
Publications dans "Cellules HepG2" :
4 publications dans cette catégorie
Affiliations :
Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br.
Immunology Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil. luis.andrade@unifesp.br.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Hospital Geral de Goiânia Alberto Rassi, Goiânia, GO, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Departamento de Patologia Clínica e Anatomia Patológica, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Faculdade de Medicina, Hospital das Clinicas HCFMUSP, Universidade de Sao Paulo, São Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Department of Clinical Pathology, School of Medicine, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
Hermes Pardini Group, Vespasiano, MG, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Serviço de Reumatologia e Laboratório de Autoimunidade da Divisão de Laboratório Central do Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :
3 publications dans cette catégorie
Affiliations :
Sociedade Brasileira de Autoimunidade, Porto Alegre, RS, Brazil.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: liv880213@foxmail.com.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
Hainan Provincial Key Laboratory for Tropical Hydrobiology and Biotechnology, School of Marine Science, Hainan University, Haikou 570228, China. Electronic address: xiexi@hainu.edu.cn.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: 1532892231@qq.com.
Publications dans "Cellules HepG2" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: luolijie4567@163.com.
Publications dans "Cellules HepG2" :
Sulfoquinovose (6-deoxy-6-sulfo-D-glucose, SQ), the polar head group of sulfolipids in plants, is abundant in nature. Many bacteria degrade SQ through pathways termed sulfoglycolysis producing C3 or C...
Perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) are the most representative perfluoroalkyl substances that accumulate in the food chain and are harmful to the environment. The u...
Granular activated carbon (GAC) was harvested from six filter-adsorbers that are used for taste and odour control in three drinking water treatment plants in Ontario, Canada, and evaluated for the rem...
Perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) are two of the most commonly researched per- and polyfluoroalkyl substances (PFAS). Globally, many long-chain PFAS compounds incl...
Perfluoroalkyl substances (PFAS) have been associated with cancer, but the potential underlying mechanisms need to be further elucidated and include studies of PFAS mixtures. This mechanistic study re...
Alterations in bile acid (BA) profiles are closely associated with adverse outcomes in pregnant women and their offspring and may be one potential pathway underlying the related metabolic effects of p...
Humans are exposed to perfluoroalkyl acids (PFAA) mainly through direct pathways, such as diet and drinking water, but indirect exposure also occurs when PFAA precursors break down to form legacy PFAA...
A growing body of evidence suggests the deleterious effects of perfluoroalkyl substances (PFASs) on kidney, but little is known on the association between PFASs joint exposure and uric acid....
Serum PFASs concentrations were measured in 661 participants recruited from Tianjin, China using liquid chromatography/mass spectrometry. The associations of single PFASs exposure with uric acid level...
Potassium perfluoro-1-octanesulfonate (PFOS) and perfluoro-n-octanoic acid (PFOA) were the dominated contributors with median concentrations of 16.80 ng/ml and 9.42 ng/ml, respectively. Increased PFOA...
Significant associations between PFOA and PFDA and uric acid, and between PFOA and hyperuricemia were found in the single-pollutant models, but the joint effect of PFASs mixture on uric acid was not o...
This commentary proposes an approach to risk assessment of mixtures of per- and polyfluorinated alkyl substances (PFAS) as EFSA was tasked to derive a tolerable intake for a group of 27 PFAS. The 27 P...
Perfluoroalkyl acids (PFAAs), a subset of per- and poly-fluoroalkyl substances (PFAS), are environmentally stable, mobile and bioaccumulative compounds. This leads to high concentrations in wildlife s...